Any FDA approval of an MDMA or psilocybin therapy through 2027-12-31 includes a REMS mandating monitored in-clinic dosing sessions.

If MDMA or psilocybin ever gets FDA approval, the agency will almost certainly attach strict rules requiring patients to take the drug inside a licensed clinic while staff watch over them the whole time. These rules, called a REMS (Risk Evaluation and Mitigation Strategy), are how the FDA manages especially risky medicines. You would not be able to take an approved psychedelic therapy at home.

Unresolved abuse-potential and the requirement for supervised administration during psychoactive sessions make a restrictive REMS with mandatory monitored dosing the only defensible regulatory path; a label without such controls is implausible given prior FDA signals.